Senz recruits first patient for leukaemia trial
07 November, 2012 by Dylan Bushell-EmblingSenz Oncology has recruited the first subject for the debut human trial of oral chemotherapeutic candidate VAL-1000 in patients with acute leukaemia.
Biota reaps $4.2m from R&D Tax Incentive
07 November, 2012 by Dylan Bushell-EmblingBiota (ASX:BTA) will add a $4.2m tax credit for the December quarter to its bottom line after receiving the funds through the R&D Tax Incentive.
Bioniche partner pulls plug on Urocidin trial
06 November, 2012 by Dylan Bushell-EmblingBioniche (ASX:BNC) said its licensing partner has called off a phase III trial of Urocidin, a bladder cancer treatment, due in part to slow recruitment.
CSL trials new heart attack treatment
06 November, 2012 by Dylan Bushell-EmblingData from early studies of CSL's (ASX:CSL) lipoprotein-based treatment candidate show its potential in reducing the risk of recurrent heart attacks.
Australian colorectal cancer blood test attracts attention from US
05 November, 2012 by Dylan Bushell-EmblingQuest Diagnostics is evaluating using a biomarker-based blood test for colorectal cancer developed by Clinical Genomics, the CSIRO and the Flinders Centre for Innovation in Cancer.
Monash team wins grant for inhalable oxytocin
05 November, 2012 by Dylan Bushell-EmblingA Monash University team has won a $1 million grant to develop an inhalable oxytocin treatment for post-partum haemorrhage, a leading cause of death in emerging markets.
Meet the Science Minister’s Prize for Life Scientist of the Year: Mark Shackleton
01 November, 2012 by Tim DeanCancer researcher, Professor Mark Shackleton, has been awarded the Science Minister’s Prize for Life Scientist of the Year for his work understanding the nature of cancer.
Michelle Burke joins AusBiotech board
01 November, 2012 by Tim DeanPharmaceutical industry and policy expert, Michelle Burke, has joined the AusBiotech board, as Dr Paul Walton and Dr Peter Isdale AM depart.
Patrys cleared to extend myeloma trial
01 November, 2012 by Dylan Bushell-EmblingPatrys (ASX:PAB) has secured ethics approval to add an Australian site to its planned phase I/IIa trial of cancer drug candidate PAB-SM6 for multiple myeloma.
Medical investment today like funding mining exploration and building no mines: investor
01 November, 2012 by Tim DeanThe disparity between money invested in medical discoveries compared to commercialisation is akin to investing in mining exploration and nothing else, says Dr Jurgen Michaelis, Executive Director of newly launched Verde Capital, a venture capital fund.
AusBiotech 2012: The real ‘valley of death’ is dealing with regulators: Alan Robertson
01 November, 2012 by Tim DeanThe gap between applying for marketing approval and receiving the go-ahead from regulators is the real ‘valley of death’ facing biotechs, says Alan Robertson, CEO of Pharmaxis.
Day of Awards at AusBiotech 2012
01 November, 2012 by AusBiotechStarpharma, Vaxxas, Dr Andrew Baker and Connor O’Meara all received awards at the AusBiotech 2012 conference in Melbourne last night.
AusBiotech 2012: Future of health care depends on reforming regulators
31 October, 2012 by Tim DeanHealth regulators need a radical overhaul if the “innovation gap” between research and health care is to be bridged in the future, says Dr Richard Barker.
Phosphagenics forms horse supplement JV
31 October, 2012 by Dylan Bushell-EmblingPhosphagenics (ASX:POH) has formed a joint venture with a subsidiary of Equine Nutrition Australia to market a line of horse supplements using its TPM delivery technology.
Octa Phillip loses fight for Bioxyne
31 October, 2012 by Dylan Bushell-EmblingShareholders in Bioxyne (ASX:BXN) resisted a call by investor group Octa Phillip to remove several directors and cease development of HI 164, instead voting to remove Octa's own MD from the board.
